Latest Information
September 25, 2015

New studies of two drugs, showing that each works better than the standard treatment for advanced kidney cancer, should lead to changes in patient care, researchers said on Friday.

September 10, 2015

Researchers who studied a population-based cohort of patients with metastatic renal cell carcinoma (mRCC) found a trend toward improved survival with the shift from the cytokine to the targeted therapy era. The degree of improvement, however, was slightly less than that observed in clinical trials of targeted therapies.

August 12, 2015

Smoking is a risk factor in the clear cell and papillary subtypes of renal cell carcinoma (RCC), but not in chromophobe RCC, according to a study published in The Journal of Urology.

Print this page Tell A Friend Add to Favorites

Dr. Kevin Zbuk

B.Sc. (Alberta), MD (Alberta), FRCPC

Assistant Professor, McMaster University
Department of Oncology - Division of Medical Oncology


Juravinski Cancer Centre
3rd Floor
699 Concession Street
Hamilton Ontario, L8V 5C2

Contact Information:
P: 905-387-9711 Ext. 64602
F: 905-575-6326

Support Staff:
Karen Chadwick (Administrative Assistant)
P: 905-387-9711 Ext. 64602
F: 905-575-6326

Areas of Interest

Dr. Zbuk's areas of interest include cancer genetics and the molecular classification of gastrointestinal polyposis syndromes. Dr. Zbuk's oncology practice focuses on gastrointestinal malignancies.

Selected Publications

Zbuk K and Eng C “Cancer Phenomics: RET and PTEN as illustrative models”. Nature Reviews Cancer. 2007 Jan;7(1):35-45.

Ni Y*, Zbuk K*, Sadler T, et. al. « Germline mutations and variants in the succinate dehydrogenase genes in Cowden andCowden-like syndromes” American Journal of Human Genetics 2008 (in press)

Plon, S.E., Pirics, M.L., Agrawal, S., Zbuk, K., Nuchtern, J., Hicks, J., Hegde, M., Lip-Hon Chin, E., Eng, C., and H. Russell (2008). Multiple Tumors in a Child with Germline Mutations in TP53 and PTEN. New England J of Medicine, in press.

* joint first authors